For Investors

• Analyst Coverage
• Annual Reports
• Calendar
• Contact Investor Relations
• Financial Reports
• Frequently Asked Questions
• Information Circular
• Management and Investor Relations
• Media Coverage
• News Releases
• Presentations
• Request Documents
• SEDAR Filings
• Stock Quote
• Webcasts
• Why Invest?

News Releases ::

• Isotechnika Pharma receives National Research Council IRAP funding for NICAM program
  More...March 4, 2010
  
• European authorities accept voclosporin for regulatory review
  More...March 2, 2010
  
• Isotechnika Pharma announces sale of Isodiagnostika to Paladin Labs
  More...February 18, 2010
  

Media Coverage ::

• Isotechnika strikes strategic drug collaboration and financing deal with Paladin Labs
  More...May 7, 2009
• Edmonton business news: Brick, Churchill, Isotechnika
  More...May 7, 2009
• Paladin in joint venture for new psoriasis treatment
  More...May 7, 2009

Media Coverage

• May 7, 2009
  Isotechnika strikes strategic drug collaboration and financing deal with Paladin Labs
  Winnipeg Free Press
• May 7, 2009
  Edmonton business news: Brick, Churchill, Isotechnika
  Edmonton Journal
• May 7, 2009
  Paladin in joint venture for new psoriasis treatment
  The Gazette
• May 7, 2009
  Paladin and Isotechnika Combine Forces to Advance Latter's Immunosuppressant
  GEN News Highlights
• May 7, 2009
  Isotechnika nabs $11M in voclosporin pact
  John Carroll - Fierce Biotech
• May 27, 2008
  Isotechnika reports positive Phase 2b trial of voclosporin kidney-transplant drug
  The Canadian Press
• May 5, 2008
  Voclosporin reduces plaques, has fewer side effects than cyclosporine
  National Review of Medicine
• April 18, 2008
  Voclosporin (ISA247) psoriasis trial shows impressive results
  Psoriasis Cure Now
• April 18, 2008
  New treatment for psoriasis offers hope of fewer side effects
  OnMedica News
• April 18, 2008
  New Psoriasis Pill Appears Effective
  HealthDay